289 related articles for article (PubMed ID: 19329323)
41. N-(Anilinoethyl)amides: design and synthesis of metabolically stable, selective melatonin receptor ligands.
Rivara S; Vacondio F; Fioni A; Silva C; Carmi C; Mor M; Lucini V; Pannacci M; Caronno A; Scaglione F; Gobbi G; Spadoni G; Bedini A; Orlando P; Lucarini S; Tarzia G
ChemMedChem; 2009 Oct; 4(10):1746-55. PubMed ID: 19728346
[TBL] [Abstract][Full Text] [Related]
42. Efficient synthesis of hexahydroindenopyridines and their potential as melatoninergic ligands.
Párraga J; Moreno L; Diaz A; El Aouad N; Galán A; Sanz MJ; Caignard DH; Figadère B; Cabedo N; Cortes D
Eur J Med Chem; 2014 Oct; 86():700-9. PubMed ID: 25232966
[TBL] [Abstract][Full Text] [Related]
43. Synthesis and biological activity of new melatonin dimeric derivatives.
Di Giacomo B; Bedini A; Spadoni G; Tarzia G; Fraschini F; Pannacci M; Lucini V
Bioorg Med Chem; 2007 Jul; 15(13):4643-50. PubMed ID: 17481904
[TBL] [Abstract][Full Text] [Related]
44. Melatonin-enhanced hyperactivation of hamster sperm.
Fujinoki M
Reproduction; 2008 Nov; 136(5):533-41. PubMed ID: 18715981
[TBL] [Abstract][Full Text] [Related]
45. Molecular pharmacology of the mouse melatonin receptors MT₁ and MT₂.
Devavry S; Legros C; Brasseur C; Cohen W; Guenin SP; Delagrange P; Malpaux B; Ouvry C; Cogé F; Nosjean O; Boutin JA
Eur J Pharmacol; 2012 Feb; 677(1-3):15-21. PubMed ID: 22202844
[TBL] [Abstract][Full Text] [Related]
46. Design and synthesis of naphthalenic derivatives as new ligands at the melatonin binding site MT3.
Leclerc V; Ettaoussi M; Rami M; Farce A; Boutin JA; Delagrange P; Caignard DH; Renard P; Berthelot P; Yous S
Eur J Med Chem; 2011 May; 46(5):1622-9. PubMed ID: 21377769
[TBL] [Abstract][Full Text] [Related]
47. Neurochemical properties of ramelteon (TAK-375), a selective MT1/MT2 receptor agonist.
Kato K; Hirai K; Nishiyama K; Uchikawa O; Fukatsu K; Ohkawa S; Kawamata Y; Hinuma S; Miyamoto M
Neuropharmacology; 2005 Feb; 48(2):301-10. PubMed ID: 15695169
[TBL] [Abstract][Full Text] [Related]
48. Bicyclic melatonin receptor agonists containing a ring-junction nitrogen: Synthesis, biological evaluation, and molecular modeling of the putative bioactive conformation.
Elsner J; Boeckler F; Davidson K; Sugden D; Gmeiner P
Bioorg Med Chem; 2006 Mar; 14(6):1949-58. PubMed ID: 16290939
[TBL] [Abstract][Full Text] [Related]
49. Synthesis and structure-affinity-activity relationships of novel benzofuran derivatives as MT(2) melatonin receptor selective ligands.
Wallez V; Durieux-Poissonnier S; Chavatte P; Boutin JA; Audinot V; Nicolas JP; Bennejean C; Delagrange P; Renard P; Lesieur D
J Med Chem; 2002 Jun; 45(13):2788-800. PubMed ID: 12061881
[TBL] [Abstract][Full Text] [Related]
50. (R)-2-(4-Phenylbutyl)dihydrobenzofuran derivatives as melatoninergic agents.
Sun LQ; Takaki K; Chen J; Bertenshaw S; Iben L; Mahle CD; Ryan E; Wu D; Gao Q; Xu C
Bioorg Med Chem Lett; 2005 Mar; 15(5):1345-9. PubMed ID: 15713384
[TBL] [Abstract][Full Text] [Related]
51. Nonsteroidal progesterone receptor ligands (I): synthesis and SAR of new tetrahydronaphthofuranone derivatives.
Shinei R; Kurihara K; Tanabe K; Tabata Y; Kurata Y; Hoshiko S; Okonogi T
Bioorg Med Chem; 2006 Jul; 14(14):4850-61. PubMed ID: 16580213
[TBL] [Abstract][Full Text] [Related]
52. Design of novel melatonin analogs for the reduction of intraocular pressure in normotensive rabbits.
Alarma-Estrany P; Guzman-Aranguez A; Huete F; Peral A; Plourde R; Pelaez T; Yerxa B; Pintor J
J Pharmacol Exp Ther; 2011 Jun; 337(3):703-9. PubMed ID: 21368006
[TBL] [Abstract][Full Text] [Related]
53. Toward the definition of stereochemical requirements for MT2-selective antagonists and partial agonists by studying 4-phenyl-2-propionamidotetralin derivatives.
Bedini A; Lucarini S; Spadoni G; Tarzia G; Scaglione F; Dugnani S; Pannacci M; Lucini V; Carmi C; Pala D; Rivara S; Mor M
J Med Chem; 2011 Dec; 54(24):8362-72. PubMed ID: 22047556
[TBL] [Abstract][Full Text] [Related]
54. Investigational selective melatoninergic ligands for receptor subtype MT2.
Wan N; Zhang FF; Ju J; Liu DZ; Zhou SY; Zhang BL
Mini Rev Med Chem; 2013 Aug; 13(10):1462-74. PubMed ID: 23815579
[TBL] [Abstract][Full Text] [Related]
55. Molecular basis defining the selectivity of substituted isoquinolinones for the melatonin MT
Chan KH; Tse LH; Huang X; Wong YH
Biochem Pharmacol; 2020 Jul; 177():114020. PubMed ID: 32389636
[TBL] [Abstract][Full Text] [Related]
56. Design and synthesis of 2-phenylimidazo[1,2-a]pyridines as a novel class of melatonin receptor ligands.
El Kazzouli S; Griffon du Bellay A; Berteina-Raboin S; Delagrange P; Caignard DH; Guillaumet G
Eur J Med Chem; 2011 Sep; 46(9):4252-7. PubMed ID: 21764185
[TBL] [Abstract][Full Text] [Related]
57. New quinoxaline derivatives as potential MT₁ and MT₂ receptor ligands.
Ancizu S; Castrillo N; Pérez-Silanes S; Aldana I; Monge A; Delagrange P; Caignard DH; Galiano S
Molecules; 2012 Jun; 17(7):7737-57. PubMed ID: 22732886
[TBL] [Abstract][Full Text] [Related]
58. Tetrahydroquinoline Ring as a Versatile Bioisostere of Tetralin for Melatonin Receptor Ligands.
Rivara S; Scalvini L; Lodola A; Mor M; Caignard DH; Delagrange P; Collina S; Lucini V; Scaglione F; Furiassi L; Mari M; Lucarini S; Bedini A; Spadoni G
J Med Chem; 2018 Apr; 61(8):3726-3737. PubMed ID: 29595267
[TBL] [Abstract][Full Text] [Related]
59. 2-Arylmelatonin analogues: Probing the 2-phenyl binding pocket of melatonin MT
Mari M; Elisi GM; Bedini A; Lucarini S; Retini M; Lucini V; Scaglione F; Vincenzi F; Varani K; Castelli R; Mor M; Rivara S; Spadoni G
Eur J Med Chem; 2022 Dec; 243():114762. PubMed ID: 36150258
[TBL] [Abstract][Full Text] [Related]
60. Synthesis of 2-arylfuro[3,2-b]pyridines: Effect of the C2-aryl group on melatoninergic activity.
Couhert A; Delagrange P; Caignard DH; Chartier A; Suzenet F; Guillaumet G
Eur J Med Chem; 2016 Feb; 109():268-75. PubMed ID: 26785296
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
